- The partnership between ADPHC and Organon aims to launch targeted awareness campaigns and deliver evidence-based educational resources that empower women throughout every stage of their health journey
- Both entities will collaborate on key women’s health priorities, including cardiovascular, reproductive, and maternal health, to drive meaningful health outcomes
Abu Dhabi, UAE- April 14, 2025- The Abu Dhabi Public Health Centresigned Memorandum of Understanding (MOU) withOrganon, a global healthcare company dedicated to advancing women’s health, at the 25th IUHPE World Conference on Health Promotion. Both entities will collaborate to enhance women’s health by focusing on key areas of intervention and addressing critical health challenges that uniquely or disproportionately affect women.
The MoU was signed by His Excellency Dr. Rashed Alsuwaidi, Director General of the Abu Dhabi Public Health Centre and Ramy Koussa, Middle East, Turkey and Africa Associate Vice President at Organon. The agreement marks a shared commitment to advancing women’s health outcomes in Abu Dhabi.
The partnership aims to enhance women’s health and support a healthy pregnancy journey through various initiatives. These include delivering awareness campaigns, research and sharing insights on priority women’s health conditions. Additionally, the collaboration will support the exchange of knowledge and expertise on key women’s health priorities, including cardiovascular, reproductive, and maternal health, improving healthcare for women in the Emirate and driving meaningful health outcomes. The partnership will also deliver evidence-based educational resources that empower women throughout their health journey.
HE Dr. Rashed Alsuwaidi, Director General of ADPHC commented: We are committed to prioritizing the health of women and children as a cornerstone of our vision for a healthier future. Our goal is to create a supportive healthcare environment that empowers women throughout their lives, by not only addressing immediate health needs but also supporting long-term well-being and prevention, ensuring that every woman in the Emirate has access to exceptional, tailored healthcare, adopting a proactive and preventive approach to lead healthier, longer lives.
“This partnership underscores our dedication to addressing critical challenges in women’s health both here in the UAE and throughout the region. By combining our expertise with the leadership of the Abu Dhabi Public Health Centre, we aim to create impactful programs that support women at every stage of their health journey. This collaboration will complement our broader efforts throughout the region to advance women’s health in several areas such as cardiovascular health and chronic conditions like migraine,” Koussa continued.[MA1]
Organon will also work closely with the Abu Dhabi Public Health Centre to organize educational forums, counselling sessions, and training workshops aimed at empowering women with the knowledge and resources they need to make informed health decisions. By integrating efforts and exchanging expertise, Organon aims to strengthen the support system for women across various aspects of their health, ensuring a holistic approach to their well-being.
Ends
About Abu Dhabi Public Health Centre (ADPHC)
The Abu Dhabi Public Health Centre (ADPHC), established in 2019 under the Department of Health – Abu Dhabi, is the emirate’s dedicated authority for public and preventive health. As the first of its kind in the region, ADPHC leads efforts to protect and promote community well-being through evidence-based programs targeting communicable and non-communicable diseases, occupational and environmental health, and emergency preparedness. Driven by innovation, research, and strategic partnerships, ADPHC is committed to fostering a healthier, safer society in line with Abu Dhabi’s vision for sustainable and proactive healthcare.
About Organon:
Organon is a global healthcare company formed to focus on improving the health of women throughout their lives. Organon offers more than 60 medicines and products in women’s health in addition to a growing biosimilars business and a large franchise of established medicines across a range of therapeutic areas. Organon’s existing products produce strong cash flows that support investments in innovation and future growth opportunities in women’s health and biosimilars. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.
Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 10,000 employees with headquarters located in Jersey City, New Jersey.
For more information, visit http://www.organon.com and connect with us on LinkedIn, Instagram, X (formerly known as Twitter) and Facebook.
[MA1]Suggest to combine the two quotes into one